AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines the highly specialized molecular technologies LAMP and CRISPR. By integrating these two methods, eazySNP enables the rapid and highly specific detection of genetic variants. This technological synergy was made possible through the scientific collaboration between AmplexDiagnostics and Scope Biosciences and represents a significant advancement in molecular SNP diagnostics, demonstrated by the successful introduction of the first CE-IVD product based on this technology.

With the first application of the eazySNP technology, AmplexDiagnostics targets one of the world's most significant multidrug-resistant yeast pathogens: Candidozyma auris. "eazySNP C. auris FKS1 S639" is the first CE-IVD diagnostic test of its kind and enables the highly specific detection of clinically relevant mutations in the FKS1 gene associated with echinocandin resistance. As echinocandins currently represent the first-line treatment option for C. auris infections, the rapid identification of resistance-associated variants is of considerable clinical importance. The assay is performed directly from a yeast colony on the AmplexDiagnostics eazyMini platform and delivers results within just 45 minutes. The eazySNP technology therefore provides, for the first time, a rapid and targeted molecular solution for the detection of this important resistance marker.

For Scope Biosciences, the launch represents a strategic expansion from molecular diagnostics for plant health into human molecular diagnostics.